Dingwei Ye

机构：Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, Huadong Hospital, Shanghai Cancer Institute, Pudong Medical Center

发表论文 191 篇 · 总被引 5608 次 · h-index 38

代表论文

• Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer (2024 · Prostate Cancer and Prostatic Diseases · 被引 43)
• From biology to the clinic — exploring liver metastasis in prostate cancer (2024 · Nature Reviews Urology · 被引 18)
• Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. (2024 · Journal of Clinical Oncology · 被引 14)
• rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC (2025 · Future Oncology · 被引 12)
• Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study. (2025 · Journal of Clinical Oncology · 被引 12)
• Calycosin inhibits the proliferation and metastasis of renal cell carcinoma through the MAZ / HAS2 signaling pathway (2024 · Phytotherapy Research · 被引 10)